2018

Recent advances in managing brain metastasis

Rupesh Kotecha
Miami Cancer Institute, rupeshk@baptisthealth.net

Minesh Mehta
*Miami Cancer Institute*, mineshm@baptisthealth.net

Check for updates

REVIEW

Recent advances in managing brain metastasis [version 1; referees: 2 approved]

Rupesh Kotecha[1,2], Vinai Gondi[3,4], Manmeet S Ahluwalia[5,6], Priscilla K Brastianos[7,8], Minesh P Mehta [ID] [1,2]

[1]Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
[2]Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
[3]Northwestern Medicine Cancer Center Warrenville, Warrenville, IL, USA
[4]Northwestern University Feinberg School of Medicine, Chicago, IL, USA
[5]Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
[6]Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
[7]Divisions of Hematology/Oncology and Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA
[8]Harvard Medical School, Boston, MA, USA

Abstract

Brain metastases are the most common malignancy encountered in the central nervous system (CNS), with up to 30-40% of cancer patients developing brain metastases at some point during the course of their disease. The management of brain metastasis is rapidly evolving and the roles of local therapies such as whole-brain radiation therapy, stereotactic radiosurgery, and resection along with systemic therapies are in flux. An emphasis on the neurocognitive side effects associated with treatment has gained prominence. Novel molecular studies have demonstrated important evolutionary patterns underpinning the development of brain metastasis and leptomeningeal disease, which may be key to unlocking new therapeutic strategies. This article provides a framework for incorporating the results of recent randomized radiotherapy clinical trials into practice, expounds upon the emphasis on cognition being an important driver in therapeutic selection, describes the importance of CNS-penetrating systemic therapies, and provides an overview of the novel molecular insights that will likely set the stage for future developments in this field.

Keywords

brain metastasis, whole brain radiation therapy, stereotactic radiosurgery, neurocognition, targeted therapy, genomic

Open Peer Review

Referee Status: ✔ ✔

	Invited Referees	
	1	**2**
version 1 published 09 Nov 2018	✔	✔

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

1 **Seema Nagpal**, Stanford University School of Medicine, USA

2 **Eric L Chang**, Keck School of Medicine of the University of Southern California, USA

Discuss this article

Comments (0)

Corresponding author: Minesh P Mehta (mmehta@nmff.org)

Author roles: Kotecha R: Writing – Original Draft Preparation, Writing – Review & Editing; **Gondi V**: Writing – Original Draft Preparation, Writing – Review & Editing; **Ahluwalia MS**: Writing – Original Draft Preparation, Writing – Review & Editing; **Brastianos PK**: Writing – Original Draft Preparation, Writing – Review & Editing; **Mehta MP**: Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

How to cite this article: Kotecha R, Gondi V, Ahluwalia MS *et al*. **Recent advances in managing brain metastasis [version 1; referees: 2 approved]** *F1000Research* 2018, **7**(F1000 Faculty Rev):1772 (https://doi.org/10.12688/f1000research.15903.1)

First published: 09 Nov 2018, **7**(F1000 Faculty Rev):1772 (https://doi.org/10.12688/f1000research.15903.1)

Introduction

Brain metastases are the most common malignancy encountered in the central nervous system (CNS). Conventional therapeutic options have included resection, whole brain radiotherapy (WBRT), and stereotactic radiosurgery (SRS), with a very limited historical role for chemotherapy. However, targeted agents with blood-brain barrier (BBB)-penetrating capabilities, as well as immune checkpoint inhibitors (ICI) are expanding the role of systemic therapies in select subsets of patients, and current research focuses on identifying the best combinatorial approaches. WBRT has served as a component of treatment for several decades, but its role is rapidly evolving. It has proven beneficial in symptomatic patients for palliative relief, as primary treatment for brain metastases in patients who are expected to experience longer-term survival and in whom other treatments are not possible, as adjuvant therapy to lower recurrence rates after either resection or SRS, and as prophylactic treatment for systemic cancers that have a greater likelihood of intracranial spread. The cognitive toxicity of WBRT, however, cannot be ignored as the long-term sequelae can significantly impact quality of life; approaches that minimize this will be reviewed. SRS has been ascendant because of a lower cognitive dysfunction profile, and we shall review current clinical trials redefining the roles of these therapies. With the advent of targeted and immunological agents, the therapeutic landscape is shifting once again, and, as we shall demonstrate, novel molecular insights will most likely set the stage for revolutionary future advances.

Overview of recent randomized radiotherapy clinical trials

Although WBRT is one of the standard treatment options for patients with brain metastasis, until recently, only one trial had compared the efficacy of WBRT vs. medical management. In 1971, the Eastern Cooperative Oncology Group (ECOG) reported on a study of 48 patients with brain metastases randomized to prednisone with or without WBRT[1]. Clinical criteria were used to assess improvement in the patients' status. WBRT prolonged both the duration of clinical remission (11 vs. 5 weeks, statistically significant, a relative improvement of 120%) and overall survival (median 14 vs. 10 weeks, relative improvement of 40%, but P = ns, underpowered to detect a survival benefit).

The value of WBRT was re-examined in the Medical Research Council (MRC) QUARTZ trial. In this study, 538 patients with non-small cell lung cancer (NSCLC) with brain metastasis unsuitable for surgery or SRS and in whom there was "uncertainty in the clinicians' or patients' minds about the potential benefit of WBRT" were randomized to dexamethasone and WBRT (20 Gy/5 fractions) versus dexamethasone and supportive care alone[2]. This trial reported no difference in quality adjusted life days (46.4 with WBRT vs. 41.7 with supportive care; the measure of quality included dexamethasone-induced issues, and dexamethasone was used in both arms) - the primary endpoint of the study - and only a five day difference in median survival[2]. What should practitioners take away from this trial? Quite simply, in patients with brain metastasis with a very short expected survival (similar to the poor outcomes observed in patients treated before the 1970s), hospice care and supportive management alone is appropriate.

The role of radiation therapy after surgery for patients with brain metastasis has been evaluated in randomized trials. The Patchell study, published 20 years ago, demonstrated that, in patients with a single brain metastasis, WBRT after surgery reduced the rate of surgical bed and distant brain relapse, and neurologic death[3]. In the more recent MD Anderson Cancer Center (MDACC) study, patients who underwent resection of brain metastasis were randomized to observation or SRS. SRS improved the 12-month rate of local control (72% vs. 45%) and median time to local recurrence (not reached vs. 7.6 months) but SRS neither reduced the rate of distant brain failure nor did it improve overall survival[4]. One important finding was the poor local control (<50% at 12-months) observed in lesions >2.5 cm, underscoring the need to improve outcomes through improved resection cavity delineation, dose-escalation, fractionated radiosurgery, or use of pre-op SRS[5]. Although this trial supports the use of SRS after surgery, physicians need to caution patients about the significant risks of distant brain and/or leptomeningeal failure in the setting of focal therapy alone[6].

In the EORTC trial, after local therapy (SRS or surgery) patients were randomized to observation or WBRT. WBRT significantly reduced intracranial relapse (both local and distant) as well as neurologic death, but without prolonging overall survival[7]. To explore SRS as an alternative to WBRT, the N107C trial compared these two modalities. Patients undergoing resection of a brain metastasis were randomized to WBRT or SRS to the resection cavity with SRS allowed to other intact metastases. The primary endpoint, cognitive deterioration-free survival, was judged to be a single standard deviation reduction in any single cognitive domain. Although there was a two week benefit in cognitive preservation in the SRS arm compared to the WBRT arm (approximately the time needed to deliver WBRT), more striking was the six-month rate of cognitive deterioration in both arms (85% for WBRT and 52% for SRS, a rather high rate of cognitive decline, not previously well-described as a consequence of SRS)[8]. The rate of surgical bed control was higher in patients who received WBRT (78% vs. 57%) as was overall brain control (70% vs. 32%). Therefore, SRS is a reasonable option for patients after surgery, but patients should be appropriately counseled about the high rates of neurocognitive decline after SRS (especially because SRS is frequently presented as modality with negligible cognitive deficits), as well as the enhanced risks of local and distant brain failure, without a survival advantage over any modality.

Two randomized trials had previously evaluated the role of WBRT in addition to SRS for patients with limited brain metastases. The benefit of WBRT in reducing local relapse (27–33% without WBRT vs. 11–19% with WBRT) as well as distant brain failure (48–64% without WBRT vs. 27–42% with WBRT) was observed in both[7,9,10]. The N0574 study re-examined this question by randomizing patients with 1–3 brain metastases to SRS with or without WBRT. Consistent with previous studies, this trial also demonstrated benefits of WBRT in reducing local failure (27 vs. 10%) and distant brain failure (30% vs. 8%)[11]. However, there was improvement in the rate of cognitive deterioration (64% vs. 92% at 3 months) as well as improvement in quality-of-life in patients treated with SRS alone. Therefore, primary SRS

is a reasonable option for patients with limited brain metastases, albeit with only modest impact on neurocognition and quality-of-life. In practice, we should carefully select the patients who receive each of these modalities and identifying patients at high risk for neurologic death or intracranial failure may help further inform these decisions[12].

The aforementioned trials have clarified the role of WBRT in patients with poor expected survival, validated the need for adjuvant radiotherapy after surgery for brain metastasis, demonstrated the advantages and limitations of SRS after surgery in comparison to WBRT, and supported the role of single modality focal therapy in patients with limited brain metastases, as long as the substantially enhanced risk of intracranial failure is acceptable to the patient.

Cognition as a key driver in therapeutic selection
Surveys of brain metastasis patients and oncology nurses reveal cognition as an important factor in patient preferences for treatment[13]. Several randomized trials have demonstrated cognitive decline following WBRT, with cognitive function measured using a validated, multi-dimensional battery of tests assessing episodic memory (HVLT-R), executive function (TMT Part B, COWA), processing speed (TMT Part A), and fine motor control (Grooved Pegboard)[8,10,11]. These studies have observed an improvement in the rate of 3-standard deviation decline of cognitive testing from baseline to 3-6 months post-treatment from 35–52% in WBRT vs. 6–24% after SRS[8,11]. Interestingly, a significant proportion of the cognitive difference between WBRT and SRS seems to selectively involve decline in HVLT-R, implying a differential sensitivity of episodic memory to WBRT.

However, demonstration of these cognitive effects has important limitations. Since most studies use a time-to-event analysis, these trials are limited in their capacity to assess for later recovery, following initial decline in cognitive function. However, since many brain metastasis patients on these trials did not live beyond six months, the relevance of such longer-term follow-up can be questioned. In addition, while trials have demonstrated cognitive and quality-of-life effects following WBRT, one study observed decline in episodic memory in addition to self-reported cognitive complaints; however, minimal correlation was seen between decline in tested versus patient-reported cognitive function[14]. Such discordance between objectively measured and patient-reported cognitive function has been seen in other cognitive disorders such as Alzheimer's dementia, and highlights the need to objectively measure cognition with performance-based neuropsychological tests along with patient-reported outcomes[15]. Alternatively, it could also provide the almost heretical conclusion that patients care less about cognitive test scores and focus more on daily life activity issues that these tests do not measure, a very sobering thought!

In a small minority of patients (less than 5%), WBRT can be associated with debilitating dementia, which represents the more severe end of the spectrum of cognitive decline reported in clinical trials[16]. This severe form of radiation-induced toxicity can manifest as progressive dementia, gait ataxia and urinary incontinence – especially in patients treated with hypofractionated schedules (>3.5 Gy/fraction)[16].

Over the past decade, there have been significant advances in the development and testing of pharmacologic and technologic approaches for reducing cognitive decline following WBRT. Memantine is a non-competitive, low-affinity, open-channel antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks pathologically excessive stimulation of NMDA receptors. In pre-clinical models, memantine has been shown to be neuro-protective and in two placebo-controlled trials it proved to be an effective treatment for vascular dementia[17–20]. RTOG 0614 randomized 554 patients with brain metastases receiving WBRT to either memantine or placebo[21]. Although this study did not meet its pre-defined endpoint, multiple other endpoints were either clinically or statistically significant. For example, patients who were randomized to the memantine arm experienced a longer time to cognitive decline as well as a reduced risk for cognitive failure following treatment (54% vs. 65%, P = 0.01). Furthermore, memantine was neuroprotective in multiple cognitive domains including executive function, processing speed, and delayed recognition.

Recently, conformal avoidance of the neural stem-cell bearing subgranular zone of the hippocampal dentate gyrus using intensity-modulated radiotherapy (IMRT) during WBRT has shown significant promise in preventing cognitive toxicity from WBRT. The production of new neurons from mitotically active neural stem cells found in the subgranular zone of the hippocampal dentate gyrus is key to the creation of new memories[22]. The results of preclinical studies show that damage to these neural stem cells from even low doses of radiation underpin radiotherapy-induced cognitive toxicity. Additional clinical studies have established a dose-response relationship between the dose received by the hippocampus and risk of post-radiotherapy decline in episodic memory[23]. Modern hippocampal avoidance (HA-WBRT) IMRT techniques have been developed to conformally avoid the hippocampal dentate gyrus while still covering the at-risk brain parenchyma[14]. RTOG 0933, a single-arm phase II trial, demonstrated that HA-WBRT was associated with highly promising preservation of memory and quality-of-life, as compared to pre-specified historical controls. Specifically, the primary endpoint on this trial, the mean relative decline in HVLT-R delayed recall score from baseline to four months was only 7%, significantly better in comparison to the 30% decline in the historical control (P <0.001). To validate these findings, NRG CC001 (ClinicalTrials.gov identifier NCT02360215), a phase III, 518-patient trial of WBRT with memantine (M) with or without hippocampal avoidance for patients with brain metastases with the primary outcome of time to neurocognitive failure (NCF) was completed and presented at the ASTRO Annual Meeting in 2018. Time to NCF failure was significantly longer in favor of HA-WBRT+M. The NCF failure rates following WBRT+M vs. HA-WBRT+M were 63.0% vs. 53.7% at four months, and 69.1% vs. 58.0% at six months (P = 0.012).

NRG CC003 (ClinicalTrials.gov identifier NCT02635009) is an ongoing randomized phase II/III trial of prophylactic

cranial irradiation with or without hippocampal avoidance for small cell lung cancer with the primary outcomes of intracranial relapse rate and six-month deterioration in episodic memory; the randomized phase II component has completed accrual.

Prior studies comparing cognitive outcomes following SRS and WBRT have not included these neuroprotective strategies that may reduce cognitive decline following WBRT. Thus, the optimal selection of SRS versus WBRT in the modern era of brain metastasis management remains an area of important investigation.

The advent of systemic therapies

Traditional cytotoxic chemotherapy had a limited role in the management of brain metastases due to the presence of the BBB and such therapies were associated with low response rates[24,25]. With the advent of targeted therapies and immunotherapy, the role of medical therapy is experiencing a resurgence. Targeted therapies have mostly been evaluated in subsets of patients with lung cancer, breast cancer, and melanoma. The use of first generation tyrosine kinase inhibitors (TKIs) that act on *EGFR*-mutant NSCLC brain metastases, such as erlotinib and gefitinib, are associated with response rates of 50–80%, and overall survival of 12–24 months[26–28]. Trials with third generation TKIs such as osimertinib are associated with response rates of 55–70% with more durable responses[29,30]. In the AURA -3 study, osimertinib yielded response rates of 70%[30]. Newer agents that target EGFR include AZD-3759[31,32] and avitinib (targets the EGFR T790M resistant mutation)[33]. In NSCLC brain metastases with *ALK* translocations, the first generation inhibitor crizotinib resulted in response rates of 18%[34]. Newer generation drugs such as alectinib[35], ceritinib[36], and brigatinib[37,38] (a combined ALK and EGFR inhibitor) with better ability to cross the BBB[39], have resulted in responses rates of 45–78%.

In breast cancer patients with brain metastases, most targeted agents have been evaluated in the HER2-positive setting[40]. Lapatinib, a small molecule TKI inhibitor of HER2, has limited activity as a single agent, and has been combined with capecitabine[41–43]. In phase II studies, the lapatinib-capecitabine combination results in response rates of 66% in radiotherapy-naive patients and 20% in radiation refractory patients[41–43]. Neratinib has demonstrated limited efficacy with responses rates of 8% in HER2-positive brain metastases[44]; however, response rates improve to 49% with capecitabine[45]. Other drugs being examined in this patient population include tucatinib and tesevatinib[46,47].

Of patients with brain metastases from melanoma, 40–50% harbor BRAF mutations, and the use of the BRAF inhibitor vemurafenib is associated with 18–20% response rates and dabrafenib yields 30–40% response rates[48,49]. Similar to breast cancer patients, higher response rates are seen in patients that are radiation naive. The dabrafenib/trematinib combination is associated with response rates of 55%[50]. The duration of response with dabrafenib and trematinib is approximately six months.

Immunotherapies represent an exciting area of research in brain metastases. Drugs that target immune surface proteins CTLA4 (ipilimumab) and programmed cell death protein 1 (PD1) (pembrolizumab and nivolumab) have been developed and evaluated in patients with lung cancer and melanoma brain metastases[51]. A phase II trial of ipilimumab demonstrated disease control rates of 25% in those who were not on steroids and 10% in patients on steroids[52]. Phase II trials of pembrolizumab showed response rates of 22% in melanoma and 33% in NSCLC[53]. The combination of ipilimumab and nivolumab is associated with response rates of 45–57% (in some studies, stable disease is included in this measure) in patients with melanoma brain metastases[54–56]. Most of the initial trials evaluated these ICIs or receptor tyrosine kinase inhibitors (RTKIs) alone in brain metastases. A number of retrospective studies have shown that these agents can safely be used with SRS and have shown improved clinical benefit compared to those treated with SRS alone, or ICIs/RTKIs alone[57]. A number of ongoing trials are therefore evaluating these agents in combination with WBRT or SRS.

With increasing CNS penetration and intracranial efficacy with systemic therapies, a current dilemma in clinical practice is the use of upfront SRS at time of brain metastasis diagnosis or delayed SRS in patients who fail systemic therapies. Retrospective data using a strategy of systemic therapy with delayed SRS are mixed, with some series demonstrating no difference in survival[58,59], while others show a detriment to patient outcome with upfront systemic therapy alone[60]. Given the limited data in this setting, a randomized study is clearly needed to determine the optimal sequencing of available therapies.

Novel molecular insights set the stage for the future

Recent advances in genomic technologies and analytic tools have enhanced our understanding of the genetics of brain metastases. Unanswered questions have included whether brain metastases are genetically heterogeneous compared to their primary tumors, and whether differential clinical responses can be explained by such genetic heterogeneity.

A massively parallel sequencing study of one matched brain metastasis and a primary breast cancer showed two *de novo* mutations and a deletion in the metastasis and not in the primary tumor[61]. In a comprehensive genomic study of 104 matched brain metastases and primary tumors across multiple histologies and a variety of treatment regimens, investigators mapped out the phylogenetic relationship between brain metastases and primary tumors[62]. An evolutionary pattern of 'branched' or divergent evolution was ubiquitously observed, meaning the primary tumor and brain metastasis shared a common ancestor, yet there was significant divergent evolution in each site. As a result of this branched evolution pattern, in more than 50% of cases, clinically actionable alterations were present in the brain metastasis, and not detected in the primary tumor. This implies that genomic characterization of the primary tumor alone to identify therapeutic targets may miss potentially clinically significant alterations in the brain metastasis. Notably, when multiple regional and anatomically distinct brain metastases were analyzed, the majority of clinically actionable alterations were shared among the intracranial sites, suggesting genomic homogeneity within the brain itself. Furthermore, extracranial metastases (as opposed

to the primary tumor) displayed divergent evolution and were not a genetic surrogate for clinically actionable alterations in the brain metastases. These data suggest that genetic heterogeneity, at least in part, contributes to divergent therapeutic responses within the same patient. This study also demonstrated that alterations in the CDK, PI3K/AKT and HER2/EGFR pathways were common in brain metastases, suggesting that targeting these pathways should be considered. Other investigations have confirmed an enrichment of the PI3K/PTEN pathway in brain metastases when compared to extracranial sites in melanoma[63], squamous cell lung cancers[64] and breast cancer[65]. FGFR amplifications are also more enriched in brain metastases from lung adenocarcinomas compared to primary tumors, and also represent a potential therapeutic target for brain metastases patients[66].

Clinical trials should be conducted to answer the question of whether targeting the alterations specific to the brain metastasis will lead to improved clinical outcomes. Large-scale molecular studies of brain metastases across multiple histologic tumor types are needed to identify additional therapeutic targets. Nevertheless, molecular analysis of brain metastasis tissue, if available as part of clinical care, should be considered to identify potential targeted therapies.

Grant information

References

F **F1000 recommended**

1. Horton J, Baxter DH, Olson KB: **The management of metastases to the brain by irradiation and corticosteroids.** *Am J Roentgenol Radium Ther Nucl Med.* 1971; **111**(2): 334–6.
PubMed Abstract | **Publisher Full Text**

2. **F** Mulvenna P, Nankivell M, Barton R, *et al.*: **Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial.** *Lancet.* 2016; **388**(10055): 2004–14.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

3. Patchell RA, Tibbs PA, Regine WF, *et al.*: **Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial.** *JAMA.* 1998; **280**(17): 1485–9.
PubMed Abstract | **Publisher Full Text**

4. **F** Mahajan A, Ahmed S, McAleer MF, *et al.*: **Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial.** *Lancet Oncol.* 2017; **18**(8): 1040–8.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

5. **F** Soliman H, Ruschin M, Angelov L, *et al.*: **Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases.** *Int J Radiat Oncol Biol Phys.* 2018; **100**(2): 436–42.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

6. **F** Atalar B, Modlin LA, Choi CY, *et al.*: **Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases.** *Int J Radiat Oncol Biol Phys.* 2013; **87**(4): 713–8.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

7. **F** Kocher M, Soffietti R, Abacioglu U, *et al.*: **Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study.** *J Clin Oncol.* 2011; **29**(2): 134–41.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

8. **F** Brown PD, Ballman KV, Cerhan JH, *et al.*: **Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.** *Lancet Oncol.* 2017; **18**(8): 1049–60.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

9. **F** Aoyama H, Shirato H, Tago M, *et al.*: **Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.** *JAMA.* 2006; **295**(21): 2483–91.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

10. **F** Chang EL, Wefel JS, Hess KR, *et al.*: **Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.** *Lancet Oncol.* 2009; **10**(11): 1037–44.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

11. **F** Brown PD, Jaeckle K, Ballman KV, *et al.*: **Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in**

Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. *JAMA.* 2016; **316**(4): 401–9.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

12. McTyre E, Ayala-Peacock D, Contessa J, *et al.*: **Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis.** *Ann Oncol.* 2018; **29**(2): 497–503.
PubMed Abstract | **Publisher Full Text**

13. **F** Lester-Coll NH, Dosoretz AP, Hayman JA, *et al.*: **Health State Utilities for Patients with Brain Metastases.** *Cureus.* 2016; **8**(7): e667.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

14. Gondi V, Pugh SL, Tome WA, *et al.*: **Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.** *J Clin Oncol.* 2014; **32**(34): 3810–6.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

15. **F** Sul J, Kluetz PG, Papadopoulos EJ, *et al.*: **Clinical outcome assessments in neuro-oncology: A regulatory perspective: Table 1.** *Neuro Oncol Pract.* 2016; **3**(1): 4–9.
Publisher Full Text | **F1000 Recommendation**

16. DeAngelis LM, Delattre JY, Posner JB: **Radiation-induced dementia in patients cured of brain metastases.** *Neurology.* 1989; **39**(6): 789–96.
PubMed Abstract | **Publisher Full Text**

17. Chen HS, Pellegrini JW, Aggarwal SK, *et al.*: **Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.** *J Neurosci.* 1992; **12**(11): 4427–36.
PubMed Abstract | **Publisher Full Text**

18. Chen HS, Lipton SA: **Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism.** *J Physiol (Lond).* 1997; **499**(Pt 1): 27–46.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

19. Orgogozo JM, Rigaud AS, Stöffler A, *et al.*: **Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).** *Stroke.* 2002; **33**(7): 1834–9.
PubMed Abstract | **Publisher Full Text**

20. Wilcock G, Möbius HJ, Stöffler A: **A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).** *Int Clin Psychopharmacol.* 2002; **17**(6): 297–305.
PubMed Abstract

21. Brown PD, Pugh S, Laack NN, *et al.*: **Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.** *Neuro Oncol.* 2013; **15**(10): 1429–37.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

22. Eriksson PS, Perfilieva E, Björk-Eriksson T, *et al.*: **Neurogenesis in the adult human hippocampus.** *Nat Med.* 1998; **4**(11): 1313–7.
PubMed Abstract | **Publisher Full Text**

23. Monje ML, Mizumatsu S, Fike JR, *et al.*: **Irradiation induces neural precursor-cell dysfunction.** *Nat Med.* 2002; **8**(9): 955–62.
PubMed Abstract | **Publisher Full Text**

24. Eichler AF, Chung E, Kodack DP, *et al.*: **The biology of brain metastases-**

translation to new therapies. *Nat Rev Clin Oncol.* 2011; **8**(6): 344–56.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

25. Fortin D: **The blood-brain barrier: its influence in the treatment of brain tumors metastases.** *Curr Cancer Drug Targets.* 2012; **12**(3): 247–59.
PubMed Abstract | **Publisher Full Text**

26. F Welsh JW, Komaki R, Amini A, *et al.*: **Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.** *J Clin Oncol.* 2013; **31**(7): 895–902.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

27. Ceresoli GL, Cappuzzo F, Gregorc V, *et al.*: **Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.** *Ann Oncol.* 2004; **15**(7): 1042–7.
PubMed Abstract | **Publisher Full Text**

28. F Mok TS, Wu YL, Ahn MJ, *et al.*: **Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.** *N Engl J Med.* 2017; **376**(7): 629–40.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

29. Ahn M, Tsai CM, Yang JC, *et al.*: **AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies.** *Eur J Cancer.* 2015; **51**(Supplement 3): S625–6.
Publisher Full Text

30. F Wu YL, Ahn MJ, Garassino MC, *et al.*: **CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).** *J Clin Oncol.* 2018; **36**(26): 2702–9.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

31. Ahn MJ, Kim DW, Cho BC, *et al.*: **Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.** | 2017 ASCO Annual Meeting Abstracts. *J Clin Oncol.* 2017; **35**(suppl 5): 2006.
Publisher Full Text

32. Cho BC, Ahn MJ, Lee JS, *et al.*: **Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.** *J Clin Oncol.* 2017; **35**(suppl 5): 2069.
Publisher Full Text

33. Wang H, Zhang L, Zheng X, *et al.*: **The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.** *J Clin Oncol.* 2017; **35**(suppl 5).
Publisher Full Text

34. F Economopoulou P, Mountzios G: **Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.** *Transl Lung Cancer Res.* 2016; **5**(6): 588–98.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

35. F Gadgeel SM, Shaw AT, Govindan R, *et al.*: **Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With *ALK*-Positive Non-Small-Cell Lung Cancer.** *J Clin Oncol.* 2016; **34**(34): 4079–85.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

36. F Crinò L, Ahn MJ, De Marinis F, *et al.*: **Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With *ALK*-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.** *J Clin Oncol.* 2016; **34**(24): 2866–73.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

37. Gettinger S, Kim D, Tiseo M: **Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials**. *International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer.* Vienna, Austria; 2016.
Reference Source

38. F Camidge DR, Kim HR, Ahn MJ, *et al.*: **Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.** *N Engl J Med.* 2018.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

39. Venur VA, Ahluwalia MS: **Targeted Therapy in Brain Metastases: Ready for Primetime?** *Am Soc Clin Oncol Educ Book.* 2016; **35**: e123–30.
PubMed Abstract | **Publisher Full Text**

40. F Venur VA, Leone JP: **Targeted Therapies for Brain Metastases from Breast Cancer.** *Int J Mol Sci.* 2016; **17**(9): pii: E1543.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

41. F Lin NU, Diéras V, Paul D, *et al.*: **Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.** *Clin Cancer Res.* 2009; **15**(4): 1452–9.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

42. Lin NU, Carey LA, Liu MC, *et al.*: **Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.** *J Clin Oncol.* 2008; **26**(12): 1993–9.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

43. F Bachelot T, Romieu G, Campone M, *et al.*: **Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.** *Lancet Oncol.* 2013; **14**(1): 64–71.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

44. F Freedman RA, Gelman RS, Wefel JS, *et al.*: **Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.** *J Clin Oncol.* 2016; **34**(9): 945–52.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

45. Freedman R, Gelman R, Melisko M, *et al.*: **TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).** *J Clin Oncol.* 2017; **35**(15_suppl): 1005.
Publisher Full Text

46. Borges VF, Ferrario C, Aucoin N, *et al.*: **Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.** *J Clin Oncol.* ASCO Meeting Abstracts, 2016; **34**(15_suppl): 513.
Publisher Full Text

47. Lin NU, Freedman RA, Miller K, *et al.*: **Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+ patients with metastatic breast cancer (BC).** *J Clin Oncol.* ASCO Meeting Abstracts 2016; **34**(15_suppl): 514.
Publisher Full Text

48. F McArthur GA, Maio M, Arance A, *et al.*: **Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicentre study.** *Ann Oncol.* 2017; **28**(3): 634–41.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

49. F Long GV, Trefzer U, Davies MA, *et al.*: **Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.** *Lancet Oncol.* 2012; **13**(11): 1087–95.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

50. F Davies MA, Saiag P, Robert C, *et al.*: **Dabrafenib plus trametinib in patients with *BRAF*^V600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial.** *Lancet Oncol.* 2017; **18**(7): 863–73.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

51. Berghoff AS, Venur VA, Preusser M, *et al.*: **Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.** *Am Soc Clin Oncol Educ Book.* 2016; **35**: e116–22.
PubMed Abstract | **Publisher Full Text**

52. F Margolin K, Ernstoff MS, Hamid O, *et al.*: **Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.** *Lancet Oncol.* 2012; **13**(5): 459–65.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

53. F Goldberg SB, Gettinger SN, Mahajan A, *et al.*: **Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.** *Lancet Oncol.* 2016; **17**(7): 976–83.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

54. Tawbi H, Forsyth P, Algazi A, *et al.*: **Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.** *J Clin Oncol.* 2017; **35**(15_suppl): 9507.
Publisher Full Text

55. Long G, Atkinson V, Menzies A, *et al.*: **A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).** *J Clin Oncol.* 2017; **35**(15_suppl): 9508.
Publisher Full Text

56. F Tawbi HA, Forsyth PA, Algazi A, *et al.*: **Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.** *N Engl J Med.* 2018; **379**(8): 722–30.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

57. Kotecha R, Miller JA, Venur VA, *et al.*: **Melanoma brain metastasis: the impact of stereotactic radiosurgery, *BRAF* mutational status, and targeted and/or immune-based therapies on treatment outcome.** *J Neurosurg.* 2018; **129**(1): 50–9.
PubMed Abstract | **Publisher Full Text**

58. F Lim SH, Lee JY, Lee MY, *et al.*: **A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.** *Ann Oncol.* 2015; **26**(4): 762–8.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

59. F Xie L, Nagpal S, Wakelee HA, *et al.*: **Osimertinib for *EGFR*-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.** *Oncologist.* 2018; pii: theoncologist.2018-0264.
PubMed Abstract | **Publisher Full Text** | **F1000 Recommendation**

60. Magnuson WJ, Lester-Coll NH, Wu AJ, *et al.*: **Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.** *J Clin Oncol.* 2017; **35**(10): 1070–7.
PubMed Abstract | **Publisher Full Text**

61. F Ding L, Ellis MJ, Li S, *et al.*: **Genome remodelling in a basal-like breast cancer metastasis and xenograft.** *Nature.* 2010; **464**(7291): 999–1005.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

62. [F] Brastianos PK, Carter SL, Santagata S, *et al.*: **Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.** *Cancer Discov.* 2015; **5**(11): 1164–77.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

63. Chen G, Chakravarti N, Aardalen K, *et al.*: **Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.** *Clin Cancer Res.* 2014; **20**(21): 5537–46.
PubMed Abstract | **Publisher Full Text** | **Free Full Text**

64. [F] Paik PK, Shen R, Won H, *et al.*: **Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and**

Evidence of Clonal Heterogeneity in Patients with Brain Metastases. *Cancer Discov.* 2015; **5**(6): 610–21.
PubMed Abstract | **Publisher Full Text** | **Free Full Text** | **F1000 Recommendation**

65. Hohensee I, Lamszus K, Riethdorf S, *et al.*: **Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.** *Am J Pathol.* 2013; **183**(1): 83–95.
PubMed Abstract | **Publisher Full Text**

66. Preusser M, Berghoff AS, Berger W, *et al.*: **High rate of *FGFR1* amplifications in brain metastases of squamous and non-squamous lung cancer.** *Lung Cancer.* 2014; **83**(1): 83–9.
PubMed Abstract | **Publisher Full Text**

Open Peer Review

Current Referee Status: ✓ ✓

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

1   **Eric L Chang** Department of Radiation Oncology, Keck School of Medicine of the University of Southern California, California, USA
    Competing Interests: No competing interests were disclosed.

2   **Seema Nagpal** Department of Neurology, Stanford University School of Medicine, Stanford, USA
    Competing Interests: No competing interests were disclosed.